Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Influence of the Preoperative C-Reactive Protein-to-Albumin Ratio on Survival and Recurrence in Patients With Esophageal Cancer

HIROSHI TAMAGAWA, TORU AOYAMA, AYAKO TAMAGAWA, KEISUKE KOMORI, YUKIO MAEZAWA, KAZUKI KANO, MASAAKI MURAKAWA, YOSUKE ATSUMI, KENTARO HARA, KEISUKE KAZAMA, MASAKATSU NUMATA, TAKASHI OSHIMA, NORIO YUKAWA, MUNETAKA MASUDA and YASUSHI RINO
Anticancer Research April 2020, 40 (4) 2365-2371; DOI: https://doi.org/10.21873/anticanres.14205
HIROSHI TAMAGAWA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rinta77-nosuke{at}amber.plala.or.jp t-aoyama{at}lilac.plala.or.jp
TORU AOYAMA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rinta77-nosuke{at}amber.plala.or.jp t-aoyama{at}lilac.plala.or.jp
AYAKO TAMAGAWA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEISUKE KOMORI
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKIO MAEZAWA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUKI KANO
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAAKI MURAKAWA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSUKE ATSUMI
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENTARO HARA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEISUKE KAZAMA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAKATSU NUMATA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI OSHIMA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIO YUKAWA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MUNETAKA MASUDA
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUSHI RINO
Department of Surgery, Yokohama City University, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Several immune-inflammatory markers are associated with cancer progression. The purpose of the present study was to clarify the influence of the preoperative C-reactive protein-to-albumin ratio (CRP/ALB ratio) on survival of patients with esophageal cancer and recurrence after curative resection. Patients and Methods: The preoperative CRP/ALB ratio was evaluated in 122 patients who underwent radical resection for esophageal cancer from 2005 to 2018. The correlations between the CRP/ALB ratio and cancer-specific overall (OS), recurrence-free (RFS) survival and the clinicopathological status were analyzed. Results: The optimal cut-off value of the CRP/ALB ratio determined using receiver operating characteristic curve analysis was 0.04. Patients were divided into two groups based on this cut-off value: the low CRP/ALB group (n=59) and the high CRP/ALB group (n=50). The OS rate at 5 years after surgery was significantly lower in the group with high CRP/ALB at 40.5% whilst it was 63.5% in the low CRP/ALB group (p=0.005). The corresponding RFS rates at 5 years after surgery were 32.5% and 48.3%, respectively, which was a statistically significant difference (p=0.007). A multivariate analysis showed that a high CRP/ALB ratio was a significant independent risk factor for poorer cancer-specific OS and RFS. Conclusion: The preoperative CRP/ALB ratio was a strong prognostic marker for patients with esophageal cancer. The surgical strategy, including procedure and perioperative care should be carefully planned for patients with a high CRP/ALB ratio.

  • Esophageal cancer
  • C-reactive protein to albumin ratio
  • overall survival
  • recurrence

Esophageal cancer is the seventh most common type of cancer and the sixth most common cause of cancer death in the world (1). The combination of neoadjuvant chemoradiotherapy and complete surgical resection has become the standard treatment for advanced esophageal cancer (2). However, although the resection rate has increased gradually, patients with esophageal cancer often develop tumor recurrence. The prognosis of patients after curative resection remains poor, with 3- and 5-year overall survival (OS) rates of 44% and 26%, respectively (3). Therefore, it is important to identify reliable predictive factors for patients with a high risk of recurrence.

The systemic inflammatory response plays an important role in carcinogenesis and tumor progression and has a poor prognostic effect in various types of cancer (4-6). Several inflammation-based prognostic scores, including the Glasgow Prognostic Score, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio have been reported to have prognostic significance in many types of malignant disease (7, 8).

In 2009, Fairclough et al. reported a simple and easy system for prediction of complications using the preoperative C-reactive protein-to-albumin ratio (CRP/ALB ratio), and found that the simple score based on this was also an independent prognostic marker (9). Recently, the preoperative CRP/ALB ratio was also reported as an independent prognostic marker in patients with various cancer types (10-19), on emergency admission (20), and in acute coronary syndrome (21). However, the prognostic value of the CRP/ALB ratio in patients with esophageal cancer is still unclear. The purpose of this study was to investigate the prognostic value of the preoperative CRP/ALB ratio in a retrospective cohort analysis.

Patients and Methods

Patient data. Patients were identified from a database of cases with primary esophageal cancer who underwent surgical treatment at Yokohama City University from January 2005 to September 2018. Patients who had undergone palliative or non-curative surgery were excluded. All patients were pathologically diagnosed with squamous cell carcinoma in clinical stage IB to III (excluding T4).

Surgical procedure. Conventional open transthoracic esophagectomy via right thoracotomy or video-assisted surgery with two- or three-field lymphadenectomy was performed, with reconstruction through the retrosternal route or posterior mediastinal route and cervical or intrathoracic anastomosis. A feeding tube was routinely placed at the stomach or duodenum. A jejunostomy catheter was routinely placed for postoperative enteral nutrition.

Perioperative care. All of the patients received the same perioperative management. Antibiotics were administered 30 min before surgical incision and every 3 h during the operation, as well as on postoperative day (POD) 2. On POD 1, enteral nutrition and ambulation training were started. On POD 5, oral intake with water and gelatinous foods was initiated and solid food was started on POD 10.

CRP/ALB ratio. The CRP/ALB ratio was calculated as the serum level of CRP divided by the serum albumin level. A CRP/ALB ratio of 0.04 was regarded as the optimum critical point of classification based on a receiver operating characteristics curve analysis (95% confidence interval=0.559-0.776; area under the curve=0.668; p=0.004; Figure 1).

Follow-up. All patients were followed-up for 5 years after surgical curative resection. The serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels were measured and computed tomography was performed at least every 3 months for 5 years at outpatient clinics. Disease recurrence was diagnosed based on tumor marker levels and radiographic evidence of a new suspicious low-density mass.

Evaluations and statistical analyses. The significance of the associations between the CRP/ALB ratio and clinicopathological parameters was determined using the chi-squared test or Fisher's exact test. OS was defined as the period from surgery until death. Recurrence-free survival (RFS) was defined as the period from surgery until recurrence or death. The OS and RFS curves were plotted according to the Kaplan–Meier method, and a log-rank test was performed to identify statistical differences between different groups. Independent prognostic factors were identified by a Cox proportional hazards regression model. Values of p<0.05 were considered to indicate statistical significance. All statistical analyses were performed using the SPSS software program (version 23.0; IBM, Armonk, NY, USA). This study was approved by the Institutional Review Board (IRB) Committee of Yokohama City University (IRB number: B191100037). Informed consent for use of the clinical data without identifying personal data was obtained in all cases.

Results

Patient characteristics. One hundred and twenty-two patients underwent esophagectomy for esophageal cancer between October 2005 and September 2018 and the preoperative albumin and CRP levels were measured in 109 cases. The patients' ages ranged from 40 to 82 years (median=68 years); 94 patients were male, and 15 were female. The median follow-up period was 72.5 months (range=13.9-125.2 months). Fifty-nine patients were classified into the low CRP/ALB group and 50 were classified into the high CRP/ALB group.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A receiver operating characteristic curve analysis of the C-reactive protein to albumin ratio in patients who underwent potentially curative surgery for esophageal cancer. Area under the curve=0.668, 95% confidence interval=0.559-0.776; p=0.004.

Clinicopathological features. Table I summarizes the background characteristics of the patients in the low and high CRP/ALB groups in the present study. There were significant differences between the two groups in sex, pathological T factor, stage and smoking habit. In the cases with low CRP/ALB ratio, the percentage of female patients was lower and the depth of invasion was greater.

Survival analyses. The cancer-specific OS rate at 5 years after surgery was 40.5% in the high CRP/ALB group and 63.5% in the group with low CRP/ALB (p=0.005). The cancer-specific OS curves are shown in Figure 2. Univariate analyses for cancer-specific OS showed that the CRP/ALB ratio was a significant prognostic factor, as were age and depth of tumor invasion (Table II). The CRP/ALB ratio was selected for the final model to be analyzed by a multivariate analysis.

The RFS rate at 5 years after surgery was 32.5% in the group with high CRP/ALB and 48.3% in that with low CRP/ALB, which was a statistically significant difference (p=0.007). The RFS curves are shown in Figure 3. The univariate analysis of factors associated with RFS showed that the CRP/ALB ratio was a significant prognostic factor, as were age and depth of tumor invasion (Table III). The CRP/ALB ratio was selected for the final model to be analyzed by a multivariate analysis.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Comparison between the C-reactive protein-to-albumin (CRP/ALB) ratio and clinicopathological factors.

Discussion

The present study examined whether or not the CRP/ALB ratio was associated with poorer cancer-specific OS in patients who underwent radical esophagectomy for esophageal cancer. Our major findings clearly indicated that the CRP/ALB ratio was an independent risk factor for cancer-specific OS and RFS in patients with esophageal cancer. Thus, our results suggest that the measurement of the preoperative CRP/ALB ratio had a clinical influence and that it should be considered in treatment strategies for esophageal cancer.

Inflammation has become widely recognized to contribute to cancer progression and metastasis (22, 23). Inflammatory cells may change the tumor microenvironment and promote tumorigenesis by increasing the proliferation, migration, and immune escape of tumor cells. Some inflammatory markers have been investigated as prognostic factors in various malignancies.

It was suggested that the expression of CRP, which is an acute-phase protein, and a decrease in the level of albumin contribute to micro-metastasis, the growth of cancer cells, or recurrence through the inhibition of apoptosis and promotion of angiogenesis because of reduced cell-mediated immunity (24-26). The characteristics of studies found in literature about the relationship between esophageal cancer and the CRP/ALB ratio are presented in Table IV. All included studies were retrospective. In 12 studies, including the present study, the CRP/ALB ratio ranged from 0.03 to 0.50 and the number of patients ranged from 63 to 633. The results showed that an elevated pre-treatment CRP/ALB ratio predicted poor OS.

An important limitation that potentially affects the available data regarding the CRP/ALB ratio in all studies is the lack of consensus regarding the most appropriate cut-off point for the CRP/ALB ratio. In the present study, we set the cut-off value of CAR as 0.04 based on the results of the ROC analysis. Similarly, most past reports have set cut-off values using a ROC analysis. There are some differences between the previous studies and the present one because of the difference in sample sizes. However, five studies conducted in Japan used very similar cut-off values (of 0.03, 0.0375, 0.04, 0.042 and 0.085, respectively) (22-26).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

A comparison of the cancer-specific overall survival rates in the high and low C-reactive protein to albumin ratio groups after potentially curative surgery for esophageal cancer.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

A comparison of the recurrence free survival rate in the groups with high and low C-reactive reactive protein to albumin ratio after potentially curative surgery for esophageal cancer.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Univariate and multivariate Cox proportional hazards analysis of clinicopathological factors for cancer-specific overall survival.

The present study was associated with some other limitations. Firstly, it was a retrospective study with a relatively small study population; thus, the results must be confirmed in another cohort or in a prospective multicenter-study. Secondly, there was a time bias in this study, as the data were collected between 2005 and 2018. Surgical procedures, postoperative chemotherapy, and perioperative care might have changed over this period. Moreover, the test method, detection reagent, and testing time for CRP and albumin might also have differed. Finally, all studies, including the present one, only analyzed cohorts from Eastern countries.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Univariate and multivariate Cox proportional hazards analysis of clinicopathological factors for recurrence-free survival.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Main characteristics of literature studies on the C-reactive protein-to-albumin (CRP/ALB) ratio.

In conclusion, the present study showed that the preoperative CRP/ALB ratio was a significant risk factor for OS and RFS in patients who underwent radical surgery for esophageal cancer. The CRP/ALB ratio is a useful biomarker that can be conveniently evaluated to identify high-risk patients with esophageal cancer.

Acknowledgements

The work was supported, in part, by the non-governmental organization Yokohama Surgical Research Group, Association of Healthcare corporation, Yoshiki Dermatology Clinic Ginza, and Social Hearth Corporation Foundation Pond Friends Association (Fukuoka Wajiro Hospital). The Authors express their sincere gratitude to Ms. Akiko Yoshida, Ms. Yuka Maruyama, Ms. Minako Igarashi and Ms. Mariko Yamauchi for their excellent data management in this study.

Footnotes

  • ↵* These Authors contributed equally to this study.

  • Authors' Contributions

    Hiroshi Tamagawa and Toru Aoyama made substantial contributions to the conception and design. Toru Aoyama, Kentaro Hara, Hiroshi Tamagawa, Ayako Tamagawa, Keisuke Komori, Yukio Maezawa, Kazuki Kano, Keisuke Kazama, Itaru Hasimoto, Masaaki Murakawa, Masakatsu Numata, Takashi Oshima, Norio Yukawa, Munetaka Masuda, and Yasushi Rino made substantial contributions to the acquisition of data, or the analysis and interpretation of data. Toru Aoyama, Keisuke Kazama, Yosuke Astumi, Hiroshi Tamagawa, Ayako Tamagawa, Kazuki Kano and Yasushi Rino were involved in drafting the article or revising it critically for important intellectual content. Toru Aoyama, Yukio Maezawa, Keisuke Kazama, Kentaro Hara, gave final approval of the version to be published. Each Author participated sufficiently in the work to take public responsibility for appropriate portions of the content; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All Authors read and approved the final article.

  • Conflicts of Interest

    The Authors declare no competing interests in association with this study.

  • Received February 23, 2020.
  • Revision received March 7, 2020.
  • Accepted March 10, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Bray F,
    2. Ferlay J,
    3. Soerjomataram I,
    4. Siegel RL,
    5. Torre LA,
    6. Jemal A
    : Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018. PMID: 30207593. DOI: 10.3322/caac.21492
    OpenUrlCrossRefPubMed
  2. ↵
    1. Lordick F,
    2. Mariette C,
    3. Haustermans K,
    4. Obermannová R,
    5. Arnold D,
    6. ESMO Guidelines Committee
    : Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27: v50-v57, 2016. PMID: 27664261.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Yuequan J,
    2. Shifeng C,
    3. Bing Z
    : Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery. Ann Thorac Surg 90: 908-913, 2010. PMID: 20732516. DOI: 10.1016/j.athoracsur.2010.05.060.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Hanahan D,
    2. Weinberg RA
    : Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011. PMID: 21376230. DOI: 10.1016/j.cell.2011.02.013
    OpenUrlCrossRefPubMed
    1. Bromberg J,
    2. Wang TC
    : Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15: 79-80, 2009. PMID: 19185839. DOI: 10.1016/j.ccr.2009.01.009
    OpenUrlCrossRefPubMed
  5. ↵
    1. Colotta F,
    2. Allavena P,
    3. Sica A,
    4. Garlanda C,
    5. Mantovani A
    : Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 30: 1073-1081, 2009. PMID: 19468060. DOI: 10.1093/carcin/bgp127
    OpenUrlCrossRefPubMed
  6. ↵
    1. McMillan DC
    : The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev 39: 534-540, 2013. PMID: 22995477. DOI: 10.1016/j.ctrv.2012.08.003
    OpenUrlCrossRefPubMed
  7. ↵
    1. Guthrie GJ,
    2. Charles KA,
    3. Roxburgh CS,
    4. Horgan PG,
    5. McMillan DC,
    6. Clarke SJ
    : The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol 88: 218-230, 2013. PMID: 23602134. DOI: 10.1016/j.critrevonc.2013.03.010
    OpenUrlCrossRefPubMed
  8. ↵
    1. Fairclough E,
    2. Cairns E,
    3. Hamilton J,
    4. Kelly C
    : Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med 9: 30-33, 2009. PMID: 19271597.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Zhou T,
    2. Hong S,
    3. Hu Z,
    4. Hou X,
    5. Huang Y,
    6. Zhao H,
    7. Liang W,
    8. Zhao Y,
    9. Fang W,
    10. Wu X,
    11. Qin T,
    12. Zhang L
    : A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer. Tumour Biol 36: 337-343, 2015. PMID: 25256672. DOI: 10.1007/s13277-014-2623-4
    OpenUrl
    1. Ni XF,
    2. Wu J,
    3. Ji M,
    4. Shao YJ,
    5. Xu B,
    6. Jiang JT,
    7. Wu CP
    : Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac J Clin Oncol 14: 402-409, 2018. DOI: 10.1111/ajco.13055
    OpenUrlPubMed
    1. Kunizaki M,
    2. Tominaga T,
    3. Wakata K,
    4. Miyazaki T,
    5. Matsumoto K,
    6. Sumida Y,
    7. Hidaka S,
    8. Yamasaki T,
    9. Yasutake T,
    10. Sawai T,
    11. Hamamoto R,
    12. Nanashima A,
    13. Nagayasu T
    : Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma. Mol Clin Oncol 8: 370-374, 2018. PMID: 29435305. DOI: 10.3892/mco.2017.1527
    OpenUrlPubMed
    1. Mao M,
    2. Wei X,
    3. Sheng H,
    4. Chi P,
    5. Liu Y,
    6. Huang X,
    7. Xiang Y,
    8. Zhu Q,
    9. Xing S,
    10. Liu W
    : C-Reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer. Oncol Lett 14: 7417-7424, 2017. PMID: 29344182. DOI: 10.3892/ol.2017.7179
    OpenUrlCrossRefPubMed
    1. Chen S,
    2. Yang X,
    3. Feng JF
    : A novel inflammation-based prognostic score for patients with esophageal squamous cell carcinoma: the c-reactive protein/prognostic nutritional index ratio. Oncotarget 7: 62123-62132, 2016. PMID: 27557504. DOI: 10.18632/oncotarget.11389
    OpenUrlPubMed
    1. Liu X,
    2. Sun X,
    3. Liu J,
    4. Kong P,
    5. Chen S,
    6. Zhan Y,
    7. Xu D
    : Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol 8: 339-345, 2015. PMID: 26310380. DOI: 10.1016/j.tranon.2015.06.006
    OpenUrlCrossRefPubMed
    1. Liu Y,
    2. Chen S,
    3. Zheng C,
    4. Ding M,
    5. Zhang L,
    6. Wang L,
    7. Xie M,
    8. Zhou J
    : The prognostic value of the preoperative C-reactive protein/albumin ratio in ovarian cancer. BMC Cancer 17: 285, 2017. PMID: 28431566. DOI: 10.1186/s12885-017-3220-x
    OpenUrlPubMed
    1. Li YJ,
    2. Yao K,
    3. Lu MX,
    4. Zhang WB,
    5. Xiao C,
    6. Tu CQ
    : Prognostic value of the C-reactive protein to albumin ratio: A novel inflammation-based prognostic indicator in osteosarcoma. Onco Targets Ther 10: 5255-5261, 2017. PMID: 29138578. DOI: 10.2147/OTT.S140560
    OpenUrlCrossRefPubMed
    1. Guo S,
    2. He X,
    3. Chen Q,
    4. Yang G,
    5. Yao K,
    6. Dong P,
    7. Ye Y,
    8. Chen D,
    9. Zhang Z,
    10. Qin Z,
    11. Liu Z,
    12. Xue Y,
    13. Zhang M,
    14. Liu R,
    15. Zhou F,
    16. Han H
    : The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer 17: 171, 2017. PMID: 28264659. DOI: 10.1186/s12885-017-3119-6
    OpenUrlPubMed
  10. ↵
    1. Kinoshita A,
    2. Onoda H,
    3. Imai N,
    4. Iwaku A,
    5. Oishi M,
    6. Tanaka K,
    7. Fushiya N,
    8. Koike K,
    9. Nishino H,
    10. Matsushima M
    : The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol 22: 803-810, 2015. DOI: 10.1245/s10434-014-4048-0
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kim MH,
    2. Ahn JY,
    3. Song JE,
    4. Choi H,
    5. Ann HW,
    6. Kim JK,
    7. Kim JH,
    8. Jeon YD,
    9. Kim SB,
    10. Jeong SJ,
    11. Ku NS,
    12. Han SH,
    13. Song YG,
    14. Choi JY,
    15. Kim YS,
    16. Kim JM
    : The C-reactive protein/albumin ratio as an independent predictor of mortality in patients with severe sepsis or septic shock treated with early goal-directed therapy. PLoS One 10(7): e0132109, 2015. PMID: 26390126. DOI: 10.1371/journal.pone.0132109
    OpenUrlCrossRefPubMed
  12. ↵
    1. Diakos CI,
    2. Charles KA,
    3. McMillan DC,
    4. Clarke SJ
    : Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15: e493-503, 2014. PMID: 25281468. DOI: 10.1016/S1470-2045(14)70263-3
    OpenUrlCrossRefPubMed
  13. ↵
    1. Nakamura K,
    2. Smyth MJ
    : Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol 95: 325-332, 2017. PMID: 27999432. DOI: 10.1038/icb.2016.126
    OpenUrl
  14. ↵
    1. Mantovani A,
    2. Allavena P,
    3. Sica A,
    4. Balkwill F
    : Cancer-related inflammation. Nature 454: 436-444, 2008. PMID: 18650914. DOI: 10.1038/nature07205
    OpenUrlCrossRefPubMed
  15. ↵
    1. Fondevila C,
    2. Metges JP,
    3. Fuster J,
    4. Grau JJ,
    5. Palacín A,
    6. Castells A,
    7. Volant A,
    8. Pera M
    : p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90: 206-215, 2004. PMID: 14710231.
    OpenUrlCrossRefPubMed
    1. Xavier P,
    2. Belo L,
    3. Beires J,
    4. Rebelo I,
    5. Martinez-de-Oliveira J,
    6. Lunet N,
    7. Barros H
    : Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet 273: 227-231, 2006. PMID: 16208475.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Jaiswal M,
    2. LaRusso NF,
    3. Burgart LJ,
    4. Gores GJ
    : Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 60: 184-190, 2000. PMID: 10646872.
    OpenUrlAbstract/FREE Full Text
    1. Wei XL,
    2. Wang FH,
    3. Zhang DS,
    4. Qiu MZ,
    5. Ren C,
    6. Jin Y,
    7. Zhou YX,
    8. Wang DS,
    9. He MM,
    10. Bai L,
    11. Wang F,
    12. Luo HY,
    13. Li YH,
    14. Xu RH
    : A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: The C-reactive protein/albumin ratio. BMC Cancer 15: 350, 2015. PMID: 25934640. DOI: 10.1186/s12885-015-1379-6
    OpenUrlCrossRefPubMed
    1. Xu XL,
    2. Yu HQ,
    3. Hu W,
    4. Song Q,
    5. Mao WM
    : A novel inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS One 10(9): e0138657, 2015. PMID: 26390126. DOI: 10.1371/journal.pone.0138657
    OpenUrlCrossRefPubMed
    1. Shao Y,
    2. Ning Z,
    3. Chen J,
    4. Geng Y,
    5. Gu W,
    6. Huang J,
    7. Pei H,
    8. Shen Y,
    9. Jiang J
    : Prognostic nomogram integrated systemic inflammation score for patients with esophageal squamous cell carcinoma undergoing radical esophagectomy. Sci Rep 5: 18811, 2015. PMID: 26689680. DOI: 10.1038/srep18811
    OpenUrlCrossRefPubMed
    1. Otowa Y,
    2. Nakamura T,
    3. Yamamoto M,
    4. Kanaji S,
    5. Matsuda Y,
    6. Matsuda T,
    7. Oshikiri T,
    8. Sumi Y,
    9. Suzuki S,
    10. Kakeji Y
    : C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer. Dis Esophagus 30: 1-5, 2017. PMID: 28881893. DOI: 10.1093/dote/dox107
    OpenUrlCrossRef
    1. Zhao Q,
    2. Chen S,
    3. Feng JF
    : A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: neutrophil lymphocyte ratio/albumin ratio. Oncotarget 8: 103535-103542, 2017. PMID: 29262582. DOI: 10.18632/oncotarget.21989
    OpenUrlCrossRefPubMed
    1. Ishibashi Y,
    2. Tsujimoto H,
    3. Hiraki S,
    4. Kumano I,
    5. Yaguchi Y,
    6. Horiguchi H,
    7. Nomura S,
    8. Ito N,
    9. Shinto E,
    10. Aosasa S,
    11. Yamamoto J,
    12. Ueno H
    : Prognostic value of preoperative systemic immunoinflammatory measures in patients with esophageal cancer. Ann Surg Oncol 25: 3288-3299, 2018. PMID: 30019304. DOI: 10.1245/s10434-018-6651-y
    OpenUrlCrossRefPubMed
    1. Yu X,
    2. Wen Y,
    3. Lin Y,
    4. Zhang X,
    5. Chen Y,
    6. Wang W,
    7. Wang G,
    8. Zhang L
    : The value of preoperative Glasgow Prognostic Score and the C-reactive protein to albumin ratio as prognostic factors for long-term survival in pathological T1N0 esophageal squamous cell carcinoma. J Cancer 9: 807-815, 2018. PMID: 29581759. DOI: 10.7150/jca.22755
    OpenUrlCrossRefPubMed
    1. Wu CC,
    2. Li SH,
    3. Lu HI,
    4. Lo CM,
    5. Wang YM,
    6. Chou SY,
    7. Chen YH
    : Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: A propensity score-matched analysis. PeerJ 6: e5655, 2018. PMID: 30258731. DOI: 10.7717/peerj.5655
    OpenUrlCrossRefPubMed
    1. Matsunaga T,
    2. Miyata H,
    3. Sugimura K,
    4. Motoori M,
    5. Asukai K,
    6. Yanagimoto Y,
    7. Takahashi Y,
    8. Tomokuni A,
    9. Yamamoto K,
    10. Akita H,
    11. Nishimura J,
    12. Wada H,
    13. Takahashi H,
    14. Yasui M,
    15. Omori T,
    16. Oue M,
    17. Yano M
    : Prognostic significance of sarcopenia and systemic inflammatory response in patients with esophageal cancer. Anticancer Res 39: 449-458, 2019. PMID: 30591494. DOI: 10.21873/anticanres.13133
    OpenUrlAbstract/FREE Full Text
    1. Zhang H,
    2. Guo XW,
    3. Yin XX,
    4. Liu YC,
    5. Ji SJ
    : Nomogram-integrated C-reactive protein/albumin ratio predicts efficacy and prognosis in patients with thoracic esophageal squamous cell carcinoma receiving chemoradiotherapy. Cancer Manag Res 11: 9459-9468, 2019. PMID: 31819611. DOI: 10.2147/CMAR.S228113
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 40, Issue 4
April 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Influence of the Preoperative C-Reactive Protein-to-Albumin Ratio on Survival and Recurrence in Patients With Esophageal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 13 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Influence of the Preoperative C-Reactive Protein-to-Albumin Ratio on Survival and Recurrence in Patients With Esophageal Cancer
HIROSHI TAMAGAWA, TORU AOYAMA, AYAKO TAMAGAWA, KEISUKE KOMORI, YUKIO MAEZAWA, KAZUKI KANO, MASAAKI MURAKAWA, YOSUKE ATSUMI, KENTARO HARA, KEISUKE KAZAMA, MASAKATSU NUMATA, TAKASHI OSHIMA, NORIO YUKAWA, MUNETAKA MASUDA, YASUSHI RINO
Anticancer Research Apr 2020, 40 (4) 2365-2371; DOI: 10.21873/anticanres.14205

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Influence of the Preoperative C-Reactive Protein-to-Albumin Ratio on Survival and Recurrence in Patients With Esophageal Cancer
HIROSHI TAMAGAWA, TORU AOYAMA, AYAKO TAMAGAWA, KEISUKE KOMORI, YUKIO MAEZAWA, KAZUKI KANO, MASAAKI MURAKAWA, YOSUKE ATSUMI, KENTARO HARA, KEISUKE KAZAMA, MASAKATSU NUMATA, TAKASHI OSHIMA, NORIO YUKAWA, MUNETAKA MASUDA, YASUSHI RINO
Anticancer Research Apr 2020, 40 (4) 2365-2371; DOI: 10.21873/anticanres.14205
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • The C-reactive Protein to Albumin Ratio (CAR) Is an Independent Prognostic Factor for Recurrence in Patients With Esophageal Cancer After Esophagectomy
  • Survival Predictors Before Preoperative Adjuvant Chemotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
  • Clinical Significance of Prealbumin Level Measurement Before Neoadjuvant Chemotherapy in Elderly Patients With Locally Advanced Esophageal Cancer
  • Preoperative and Postoperative C-Reactive Protein to Albumin Ratio (CAR) as a Prognostic Marker for Survival of Esophageal Squamous Cell Carcinoma Patients After Surgery
  • Risk Stratification by Tissue GAD1 Expression Level in Curatively Resected Esophageal Squamous Cell Carcinoma
  • Clinical Significance of Pre-treatment Circumferential Tumor Location in Patients With cStage IB-III Esophageal Squamous Cell Cancer
  • Usefulness of Nutrition and Inflammation Assessment Tools in Esophageal Cancer Treatment
  • Modified Geriatric Nutrition Risk Index as a Prognostic Predictor for Unresectable/Recurrent Esophageal Cancer
  • Albumin and Neutrophil-to-Lymphocyte Ratio Score in Neoadjuvant Concurrent Chemoradiotherapy for Esophageal Cancer: Comparison With Prognostic Nutritional Index
  • Can D3 Lymph Node Dissection for Patients With Colon Cancer With a Poor C-Reactive Protein/Albumin Ratio Improve Survival Outcomes?
  • Prognostic Significance of Combined Platelet Distribution Width and C-Reactive Protein Score in Esophageal Cancer
  • Google Scholar

More in this TOC Section

  • Preoperative Cachexia Index Predicts Overall Survival Following Curative Resection for Remnant Gastric Cancer
  • Effect of Increased Image Matrix on Lung Nodule Volumetry in Chest CT: A Phantom Study
  • Prognostic Impact of the Geriatric Nutritional Risk Index in Elderly Patients With Colorectal Cancer
Show more Clinical Studies

Keywords

  • Esophageal cancer
  • C-reactive protein to albumin ratio
  • overall survival
  • recurrence
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire